Orlistat in hypertensive overweight/obese patients: Results of a randomized clinical trial

Journal of Hypertension

Volumn 21, Issue 11, 2003, Pages 2159-2165

  Bloch, Katia Vergetti ^a,d   Salles, Gil Fernando ^b   Muxfeldt, Elizabeth Silaid ^c   Da Rocha Nogueira, Armando ^c  

^a Hypertension Program   (Brazil)

^b Medical School   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d INSTITUTO DE PESQUISAS JARDIM BOTÂNICO DO RIO DE JANEIRO   (Brazil)

Author keywords

Hypertension; Lipase inhibitor; Lipid profile; Orlistat; Overweight obesity; Trial; Weight loss

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC OBESITY; DIASTOLIC BLOOD PRESSURE; DRUG INDICATION; FEMALE; HUMAN; HYPERTENSION; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 1542270193     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200311000-00026     Document Type: Article

References (33)

1. Lessa I. Epidemiologia da hipertensão arterial sistêmica e da insuficiência cardiaca no Brasil. Rev Bras Hipertens 2001; 8:383-392.
2. Bloch KV, Klein CH, Silva NAS, Nogueira AR, Campos LHS. Hipertensão arterial e obesidade na Ilna do Governador, Rio de Janeiro. Arq Bras Cardiol 1994; 62:17-22.
3. Kannel WB, Zhang T, Garrison RJ. Is obesity-related hypertension less of a cardiovascular risk? The Framingham Study. Am Heart J 1990; 120:1195-1201.
4. Masuo K, Mikami H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001; 14:530-538.
5. McAlister FA, Lewanczuk RZ, Teo KK. Resistant hypertension: an overview. Can J Cardiol 1996; 12:822-828.
6. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
7. Sichieri R, Coitinho DC, Leão MM, Recine E, Everhart JE. High temporal, geographic, and income variation in body mass index among adults in Brazil. Am J Public Health 1994; 84:793-798.
8. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001; 5: 1-81.
9. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chron Dis 1967; 20:637-648.
10. Armitage P. Attitudes in clinical trials. Stat Med 1998; 17:2675-2683.
11. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
12. Executive Summary of the 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). JAMA 2001; 285:2486-2497.
13. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomized controlled trials. BMJ 1999; 319:670-674.
14. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-1069.
15. StataCorp 2001. Stata statistical software: release 7.0. College Station, TX: Stata Corporation.
16. Moher D, Schultz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001; 357: 1191-1194.
17. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001; 14:304S-309S.
18. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16:2013-2017.
19. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25: 303-308.
20. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obesity 2001; 25:1713-1721.
21. Nedel FB, Rocha M, Pereira J. Years of life lost by mortality: a component of the burden of disease. Rev Saúde Pública 1999; 33:461-469.
22. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-172.
23. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235-242.
24. Bakris G, Calhoum D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20: 2257-2267.
25. Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69:1108-1116.
26. Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000; 248:245-254.
27. Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, et al. The effect of orlistat-induced weight loss concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002; 162:2428-2435.
28. Reaven G, Segal K, Hauptman J, Boldrim M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87:827-831.
29. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20:1873-1878.
30. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002; 4:415-423.
31. Keating G, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001; 61:2107-2119.
32. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21:1288-1294.
33. Jadad A. Randomized controlled trials. London: BMJ Books, 1998.